Free Trial
NASDAQ:HLVX

HilleVax Q2 2023 Earnings Report

HilleVax logo
$1.85 -0.03 (-1.60%)
Closing price 03:59 PM Eastern
Extended Trading
$1.84 -0.01 (-0.27%)
As of 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HilleVax EPS Results

Actual EPS
-$0.74
Consensus EPS
-$0.85
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

HilleVax Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

HilleVax Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Monday, August 14, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

HilleVax's Q1 2025 earnings is scheduled for Thursday, May 8, 2025

HilleVax Earnings Headlines

Analysts Set HilleVax, Inc. (NASDAQ:HLVX) PT at $3.00
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
See More HilleVax Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HilleVax? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HilleVax and other key companies, straight to your email.

About HilleVax

HilleVax (NASDAQ:HLVX), a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

View HilleVax Profile

More Earnings Resources from MarketBeat